Intangible Assets

CCRD appears to have some brand and product recognition in its niche, but the available filing-level evidence does not show the kind of proprietary IP or regulatory exclusivity that would create durable pricing power versus larger healthcare IT peers.

Its moat from intangible assets is weaker than peers with deeper clinical data assets or broader platform ecosystems, so customer retention is more likely driven by workflow fit than by unique assets that are hard to replicate.

The absence of disclosed long-run margin or ROIC history in the provided metrics limits evidence that intangible assets have translated into sustained peer-leading economics over a full cycle.

Switching Costs

CCRD likely benefits from workflow integration and implementation friction because healthcare software customers face disruption costs when changing core systems, which supports retention better than in more modular software categories.

Switching costs are still below stronger peers with enterprise-wide platforms and embedded data workflows, because the available evidence does not indicate that customers are operationally dependent on CCRD for mission-critical, system-of-record functionality.

The TTM ROIC of about 7.0% and ROCE of about 9.3% suggest some retention and monetization power, but not enough to indicate exceptional lock-in versus top-tier healthcare software peers.

Network Effects

CCRD does not appear to operate a broad two-sided marketplace or data network where each additional customer materially increases value for other customers, so network effects are limited versus platform peers.

Any data accumulation benefits are likely localized to product workflows rather than self-reinforcing ecosystem effects, which makes the moat less durable than peers with large shared datasets or interoperable networks.

Because customer value is primarily delivered through software utility rather than participant-to-participant interaction, network effects are not a major source of pricing power or retention.

Cost Advantage

CCRD may have some scale-related operating leverage in software delivery, but the provided metrics do not show a clear cost structure advantage that would consistently undercut peers on price while preserving margins.

The TTM asset turnover of about 0.48 suggests a capital-light model, yet that is common in software and does not by itself establish a durable cost advantage versus comparable vendors.

Without evidence of materially superior gross margins or a structurally lower support and implementation cost base, cost advantage looks modest rather than decisive.

Efficient Scale

CCRD likely serves a specialized healthcare software niche where market size can support a few meaningful vendors, but the evidence does not show a protected local monopoly or a capacity-constrained market that would prevent new entry.

Efficient scale is therefore weaker than for peers with dominant regional or regulatory bottlenecks, because customers still appear to have credible alternatives and switching is not prohibitively difficult.

The company’s moderate profitability metrics indicate some scale benefits, but not enough to imply that the market structure itself materially shields CCRD from competition over 5–10 years.

Overall Score

CCRD shows a modest moat mainly from workflow-based switching costs and some niche specialization, but it lacks the stronger structural advantages seen in peers with dominant ecosystems, network effects, or clear proprietary data advantages.